|Bid||304.80 x 900|
|Ask||305.40 x 1100|
|Day's range||293.60 - 318.79|
|52-week range||102.66 - 497.49|
|Beta (5Y monthly)||1.31|
|PE ratio (TTM)||18.38|
|Earnings date||23 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||304.92|
Some Americans could prefer Moderna's booster because of perceptions that it offers higher efficacy.
Moderna has been one of this year's stock market stars. The biotech company has been on everyone's radar screen as it commercialized its coronavirus vaccine and generated billions of dollars in revenue and profit.
Moderna (NASDAQ: MRNA) and AstraZeneca (NASDAQ: AZN) compete against each other in some markets with their respective COVID-19 vaccines. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Moderna's and AstraZeneca's mRNA candidate could be a winner.